<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144563">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01842685</url>
  </required_header>
  <id_info>
    <org_study_id>216/12</org_study_id>
    <nct_id>NCT01842685</nct_id>
  </id_info>
  <brief_title>Bladder Thermal Distention for Patients With Refractory Overactive Bladder</brief_title>
  <acronym>OAB</acronym>
  <official_title>Bladder Thermal Distention for Patients With Refractory Overactive Bladder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assaf-Harofeh Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assaf-Harofeh Medical Center</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigators will evaluate the efficacy of Bladder Thermal Distention
      (BTD) in patients with overactive bladder syndrome who failed previous treatment of
      anticholinergic drugs.

      The investigators' hypothesis is that it will improve the storage symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusion criteria:

        1. Patients with overactive bladder syndrome

        2. Detrusor Overactivity proven in urodynamic test

      Exclusion criteria:

        1. Mixed urinary incontinence

        2. Active urinary tract infection

        3. Urethral Stricture

      Outcome measures:

        1. Bladder Diaries

        2. Urgency questionnaire
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Urgency Questionnaire</measure>
    <time_frame>up to 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patients will complete the validated USIQ questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Daily frequency of micturitions on Bladder Diary</measure>
    <time_frame>up to 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patients will complete bladder diaries before and after the procedure. Frequencies of micturitions per day will be documented</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>Bladder Thermal Distention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continuous irrigation of the bladder with warm saline (up to 45 Celsius) using a specific 3 ways catheter. The procedure will last 1 hour. Saline will be irrigated by the PelvixTT system.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bladder Thermal Distention</intervention_name>
    <description>Bladder Thermal Distention is an approved procedure in Europe from 2006. The treatment is hydrodistention of the bladder with a warm saline (up to 45C). The procedure lasts 1 hour. The saline is infused constantly through a 3 ways specific catheter (Unithermia 18F) by the PelvixTT system.</description>
    <arm_group_label>Bladder Thermal Distention</arm_group_label>
    <other_name>PelvixTT - Hyperthermia Elmedical LTD, Israel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with overactive bladder syndrome

          -  Detrusor Overactivity proven in urodynamic test

        Exclusion criteria:

          -  Mixed urinary incontinence

          -  Active urinary tract infection

          -  Urethral Stricture
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kobi Stav, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assaf Harofe MC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kobi Stav, MD</last_name>
    <phone>972-8-9778461</phone>
    <email>stavkobi@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assaf Harofe MC</name>
      <address>
        <city>Tel Aviv Region</city>
        <state>Zeriffin</state>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kobi Stav, MD</last_name>
      <phone>972-8-9779400</phone>
      <email>stavkobi@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Kobi Stav, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 25, 2013</lastchanged_date>
  <firstreceived_date>April 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Overactive Bladder</keyword>
  <keyword>Bladder Distention</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dilatation, Pathologic</mesh_term>
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
